Results for the substance mifamurtide

Mifamurtide is an immunomodulator used for the treatment of unresectable or metastatic osteosarcoma in young patients. It works by activating macrophages and monocytes, stimulating the immune response against tumor cells.

The medication is administered via intravenous infusion, usually twice a week, with the duration of treatment determined by the physician. Common side effects include fever, chills, fatigue, and nausea.

Mifamurtide is contraindicated in patients with hypersensitivity to the active substance or severe autoimmune conditions. Its use also requires careful monitoring to prevent severe adverse reactions.

This medication is an innovative option for patients with osteosarcoma, helping to improve survival and reduce disease progression.